UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025769
Receipt number R000029631
Scientific Title Evaluation of the flare levels and central macular thickness after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema patients
Date of disclosure of the study information 2017/01/20
Last modified on 2019/02/01 15:13:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the flare levels and central macular thickness after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema patients

Acronym

Flare levels and central macular thickness after intravitreal injection in diabetic macular edema

Scientific Title

Evaluation of the flare levels and central macular thickness after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema patients

Scientific Title:Acronym

Flare levels and central macular thickness after intravitreal injection in diabetic macular edema

Region

Japan


Condition

Condition

Diabetic macular edema

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the inflammatory and therapeutic reaction to intravitreal aflibercept (IVA), ranibizumab (IVR) or triamcinolone acetonide (IVTA) in patients with diabetic macular edema (DME).

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Flare intensity
Central macular thickness

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

ranibizumab

Interventions/Control_2

aflibercept

Interventions/Control_3

triamcinolone acetonide

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

more than 20 years old

Patients diagnosed as type 2 diabetic mellitus with diabetic macular edema (more than 350 um in central retinal thickness)

Patients gave informed consent

Key exclusion criteria

Unconteroled hypertension and renal diseases

Allergy for drugs

plegnant women


Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshihiro Takamura

Organization

University of Fukui

Division name

Ophthalmology

Zip code


Address

23-3 Shimoaiduki Matsuoka Eiheiji Yoshida Fukui

TEL

+81-776-61-8403

Email

ytakamura@hotmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Yoshihiro Takamura

Organization

University of Fukui

Division name

Ophthalmology

Zip code


Address

23-3 Shimoaiduki Matsuoka Eiheiji Yoshida Fukui

TEL

+81-776-61-8403

Homepage URL


Email

ytakamura@hotmail.com


Sponsor or person

Institute

University of Fukui

Institute

Department

Personal name



Funding Source

Organization

University of Fukui

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 01 Month 20 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 10 Month 25 Day

Date of IRB


Anticipated trial start date

2017 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 01 Month 20 Day

Last modified on

2019 Year 02 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029631


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name